Direct compression of pharma-grade decloxizine hydrochloride API requires a pre-blending strategy when the active weight per tablet falls below 25 mg because cohesive fines and agglomerates generated during milling create potency pockets that are not corrected by prolonged tumbling alone. The hydrochloride salt is screened through a 500 µm stainless steel sieve or equivalent before charging into a bin blender with a fill volume not exceeding 65% of rated capacity. Geometric pre-blending with lactose monohydrate or dibasic calcium phosphate dihydrate is used; active-to-diluent ratios of 1:5 to 1:10 are evaluated during formulation development, and the selected ratio must pass blend uniformity sampling at 10 time points with an acceptance value not greater than 15.0 under USP <905>. Microcrystalline cellulose is added as a deformation agent, croscarmellose sodium at 2.0% to 4.0% w/w as a disintegrant, colloidal silicon dioxide at 0.2% to 0.5% w/w as a glidant, and magnesium stearate at 0.5% w/w as a lubricant; magnesium stearate is introduced only at the final blending stage and mixed for 3–5 min to avoid hydrophobic film formation on drug particles. Compression is carried out on a rotary press with turret speed and precompression force selected to maintain dwell time appropriate for plastic deformation of microcrystalline cellulose; tablet hardness is maintained between 40 N and 80 N, and friability remains below 1.0% mean weight loss according to USP <1216>. Dissolution testing in 0.1 N HCl at 37±0.5 °C uses Apparatus 2 at 50 rpm or Apparatus 1 at 100 rpm; the method, media volume and sampling points are justified in the regulatory dossier rather than assumed from salt solubility. A hypromellose-based film coating is applied in a perforated pan coater to a weight gain of 2.0% to 3.0% w/w to protect the tablet from light and mechanical edge erosion, and the coating formulation avoids plasticizer grades that interact with the hydrochloride salt under accelerated stability at 40 °C/75% RH.

When capsule filling is selected instead of tablet compression, the powder flow requirement changes because the tamping pin or dosator must form a stable plug in the dosing disk at production speeds that commonly exceed 50,000 capsules per hour. The decloxizine hydrochloride is dry-blended with pregelatinized starch, lactose monohydrate, sodium starch glycolate and talc; the blend is characterized by bulk density, tapped density and Carr index, with a target Carr index below 25% for reproducible tamping pin filling. Capsule fill weight variation is controlled to ±4% of target weight by in-process check weighing, and stratified discharge sampling is performed because low-density API-rich dust may rise to the top of the powder bed during prolonged machine vibration. Dosator-type machines often require denser granulation to reduce powder loss, while tamping pin machines can run lower-density powder blends but increase the risk of compaction variability; the machine configuration is therefore established after measuring powder flow function coefficients on an annular shear cell. Dissolution is tested in 0.1 N HCl at 37±0.5 °C using a sinker to prevent capsule floating; capsule shell moisture is conditioned to 13.0% to 16.0% because overdried shells become brittle and moist shells cross-link during storage, delaying disintegration beyond USP <701> limits. The finished hard gelatin or hypromellose capsule is then packaged in aluminum/PVC blister packs with desiccant when long-term stability indicates moisture uptake above 0.5% in the fill.

Wet Granulation, Binder Migration, and Loss-on-Drying Control in Granule-Based Decloxizine HCl Batches

In low-dose granule production, wet granulation is selected when direct compression cannot maintain content uniformity or when the terminal dosage form is a single-dose sachet containing oral granules. Aqueous binder solutions of povidone K30 at 2.0% to 5.0% w/w or pregelatinized starch at 5.0% to 8.0% w/w are sprayed onto the powder bed in a high-shear granulator; impeller speed, chopper speed and wet massing time are controlled because binder migration to the granule surface becomes a critical failure mode when the drying rate is excessive, leaving an API-rich outer shell that dissolves quickly and a binder-rich core that resists disintegration. Drying is conducted in a fluid-bed dryer with inlet air temperature between 50 °C and 65 °C until loss on drying reaches 1.0% to 2.5%; over-drying below 0.5% LOD increases fines and weakens granule bonding, while under-drying above 3.0% LOD causes sticking during compression or sachet caking. The dried material is passed through an oscillating granulator fitted with a 0.8 mm or 1.0 mm screen, and oversized granules are re-milled gently to avoid heat-induced agglomeration of the hydrochloride salt. Granule particle size distribution, bulk density, tapped density and residual moisture are controlled in-process by sieve analysis and Karl Fischer titration according to USP <921>; the final granule blend must pass USP <905> before compression or sachet filling. Terminal products include film-coated tablets, hard gelatin capsules filled with granules, or single-dose oral granules in aluminum foil sachets; the sachet presentation is filled by volumetric filler under nitrogen purge when oxidation-sensitive degradation products are observed in stability batches.

What Controls the Preserved Oral Solution Dosage Form When the Hydrochloride Salt Is Dissolved?

For preserved oral liquids, the hydrochloride salt requires acidified aqueous media because the protonated form contributes to solubility and free base precipitation becomes possible as pH moves above 5.5. The solution pH is maintained between 3.0 and 4.0 with citrate or phosphate buffer; the exact buffer species and molarity are selected only after forced degradation studies show no pH-catalyzed degradation of decloxizine hydrochloride or the preservative. Sorbitol or sucrose is used for palatability, glycerin is used to reduce low-temperature crystallization, and disodium edetate is added at 0.005% to 0.02% w/v to chelate trace metals that accelerate oxidative degradation. Preservative efficacy is maintained with sodium benzoate at 0.1% to 0.2% w/v in acid solution, but the system loses activity above pH 5.0 because benzoic acid ionizes; combination with a paraben ester is evaluated only when the formulation pH cannot remain below the critical ionization point. Antimicrobial preservation testing is conducted per USP <51> and EP 5.1.3 with inoculum challenge counts measured at 14 and 28 days; the product is rejected if any bacterial count increases from day 14 to day 28. The finished oral solution is filled into amber glass bottles with child-resistant closures, and closure integrity is verified according to USP <660> packaging requirements. Terminal product storage is supported by photostability testing under ICH Q1B and freeze-thaw cycling if the label allows refrigerated transport.

When Aseptic Processing Replaces Terminal Steam Sterilization for Injectable Decloxizine HCl

Parenteral dosage forms of decloxizine hydrochloride are developed as small-volume injections in Water for Injection, and the selection of aseptic filtration over terminal steam sterilization must be justified by thermal stability data generated on the formulated solution. If terminal sterilization is selected, a 121 °C saturated steam cycle with an F0 value not less than 8.0 minutes is applied only when assay and related substances remain within specification after processing; published stability data for decloxizine hydrochloride under these exact thermal conditions is limited, so most early-stage development work evaluates aseptic filtration through a 0.22 µm sterilizing-grade PVDF or PES membrane followed by filling in a Grade A zone under Grade B support per EU GMP Annex 1. The solution is tonicity-adjusted with sodium chloride to 290 mOsm/kg, checked by freezing-point osmometry under USP <785>, and purged with nitrogen if oxygen-sensitive degradation products are observed during forced oxidation studies. Bacterial endotoxin limits are derived from the K/M formula in USP <85>; for a non-intrathecal parenteral, K is 5.0 EU/kg and M is the maximum bolus dose in kilograms, producing a container endotoxin limit that must be met by depyrogenation of the vial, stopper and fill path. Particulate matter is tested by light obscuration under USP <788>, with small-volume parenteral limits of 6000 particles ≥10 µm per container and 600 particles ≥25 µm per container; visual inspection is governed by USP <790>. Type I borosilicate glass vials and elastomeric closures are specified under ISO 8362 and ISO 15378:2017, and extractables and leachables are controlled through closure migration studies in the final solution. The terminal product is a sterile aqueous injection with a long-term stability protocol that monitors pH, assay, related substances, particulate matter, endotoxin and container integrity.

For lyophilized injectable presentations, development proceeds only when the aqueous solution does not demonstrate acceptable chemical stability in the target shelf life, because freeze-drying adds thermal and mechanical stress that can convert a stable solution into a partially degraded cake. The frozen bulk solution includes a bulking agent such as mannitol or trehalose at 3.0% to 5.0% w/v, with the bulking agent selected by differential scanning calorimetry and freeze-drying microscopy to avoid collapse below the critical formulation temperature. The solution is filled, frozen on shelves at −45 °C or lower, primary-dried below the collapse temperature with chamber pressure between 50 mTorr and 150 mTorr, and secondary-dried at 25 °C to 40 °C until cake moisture is below 3.0% by Karl Fischer titration under USP <921>. Reconstitution time, pH, osmolality, particulate matter and residual moisture are release-tested; the reconstituted solution must meet USP <788> particulate limits and USP <85> endotoxin limits. The sterile powder is sealed under partial vacuum or nitrogen in Type I glass vials with vented stoppers, and stopper moisture uptake after lyophilization is checked because a wet stopper transfers moisture back into the cake and increases reconstitution haze. Terminal product acceptance includes full container closure integrity testing by vacuum decay or helium leak after capping, and the product is stored at controlled room temperature unless stability data supports cold-chain handling.